What is the recommended immediate assessment and management for a patient presenting with acute flaccid paralysis?

Acute flaccid paralysis: Immediate assessment and management

Bold, time-critical recommendation: Secure airway and breathing first; admit to ICU if any signs of respiratory or bulbar compromise, start disease-specific therapy without waiting for confirmatory tests (IVIg or plasma exchange for suspected GBS; antitoxin immediately for suspected botulism). 1, 2

1) Triage for life-threatening causes (minutes)

• Respiratory failure risk (any one → ICU/intubation threshold):
  • Dyspnea at rest/talking, single-breath count <15, accessory muscle use, tachypnea/tachycardia, paradoxical breathing, weak cough/secretions, dysphagia/dysarthria, nasal voice/drooling; VC <15–20 mL/kg or <1 L; abnormal ABG/SpO2. Use EGRIS to estimate 1-week ventilation risk in suspected GBS. 1
• Bulbar/autonomic instability:
  • Dysphagia, impaired gag, brady/tachyarrhythmias, labile BP → ICU. Continuous cardiac and BP monitoring. 1, 2
• Rapidly ascending weakness or inability to lift arms off bed → anticipate prolonged ventilation; consider early tracheostomy if intubated and high-risk. 1

Pitfalls to avoid:

• Waiting for CSF/EMG/antibody tests before treatment in GBS/botulism. 1, 2
• Missing “placid” face in botulism masking distress; look for paradoxical abdominal movement. 2

2) Focused bedside differentiation to guide immediate therapy (parallel with stabilization)

• Suspect GBS (most common AFP; symmetric ascending weakness ± paresthesias, areflexia; may have facial diplegia; autonomic signs). Start IVIg 0.4 g/kg/day ×5 days or plasma exchange 200–250 mL/kg (5 exchanges), not both sequentially. Treat if unable to walk independently or rapidly progressive/cranial/bulbar/autonomic/respiratory involvement. Do not delay for tests. 1
• Suspect botulism (descending symmetric paralysis with early cranial neuropathies: diplopia, ptosis, dysarthria, dysphagia; autonomic symptoms: dry mouth, mydriasis; normal sensation):
  • Administer heptavalent botulinum antitoxin (BAT) immediately—ideally within 24 h, up to 48 h; do not wait for lab confirmation. Continue aggressive respiratory monitoring; many require early intubation. Contact public health/CDC for BAT and testing. 2
• Red flags for spinal cord/anterior horn (urgent MRI spine):
  • Sensory level, sphincter dysfunction, severe back pain, asymmetric flaccid limb weakness with areflexia and gray-matter–predominant lesions (think AFM), trauma/compression signs → emergent MRI to exclude compressive myelopathy (neurosurgical consult). 1
• Metabolic/toxic mimics to reverse now:
  • Potassium, magnesium, phosphate, glucose, TSH; treat severe hyperkalemia immediately if present (can fully reverse paralysis). Obtain drug/toxin exposures. 1, 3

3) Immediate diagnostics (do not delay time-sensitive therapy)

• Labs: CBC, CMP (electrolytes, LFTs, renal), glucose, Mg/Phos; troponin if dysautonomia. Infectious testing guided by context. 1
• CSF: early LP to exclude mimics; albuminocytologic dissociation supports GBS but can be normal in first week; pleocytosis >50/µL suggests alternative (infection, leptomeningeal disease). 1
• Electrodiagnostics: EMG/NCS to support GBS subtype; not required acutely; repeat in 3–8 weeks if initially equivocal. 1
• Imaging: MRI spine if suspicion for cord/anterior horn involvement, AFM, or compression; gadolinium may show nerve root enhancement in GBS (supportive, nonspecific). 1
• Botulism testing: coordinate serum/stool/wound specimens urgently with public health; do not delay antitoxin. Continuous rhythm/BP monitoring; frequent neuro–respiratory checks. 2

4) Disease-directed acute treatment (prioritize morbidity, mortality, QoL)

• Suspected GBS:
  • Start ONE of:
    • IVIg 0.4 g/kg/day ×5 days, or
    • Plasma exchange (5 exchanges over ~7–14 days).
  • Admit (often ICU) if any respiratory, bulbar, autonomic signs or rapid progression. DVT and pressure-injury prophylaxis; pain control; early physio. Monitor for treatment-related fluctuations. 1
• Suspected botulism:
  • Give BAT immediately; intubate early if bulbar/respiratory compromise. Serial spirometry/EtCO2/ABGs; cardiac and BP monitoring; manage ileus/urinary retention; prevent VAP/DVT. 2
• If compressive myelopathy suspected: emergent MRI and neurosurgical decompression pathway. 1
• If metabolic/toxic cause: correct the abnormality urgently (e.g., hyperkalemia protocol) and remove exposure. 1, 3

5) Ongoing monitoring and supportive care

• Hourly-to-frequent assessments in unstable/rapidly progressive cases:
  • Respiratory mechanics (VC, NIF/SNIP, single-breath count), work of breathing, bulbar function; telemetry and frequent BP checks; secretion clearance and aspiration prevention. 1, 2
• Escalate promptly with any deterioration; most botulism intubations occur within first 48 h of hospitalization. 2

Common pitfalls and how to avoid them:

• Delaying IVIg/plasma exchange or BAT pending tests. Start immediately when clinical suspicion is high. 1, 2
• Missing autonomic instability in GBS—use continuous monitoring to prevent sudden arrhythmic death. 1
• Over-reliance on early normal CSF in GBS—up to 50% normal in week 1. 1
• Under-recognizing AFM or cord compression—obtain urgent MRI if sensory level/sphincters/asymmetry/back pain present. 1

Decision summary (first hour):

• Airway/breathing/circulation; ICU if any risk markers. 1, 2
• If ascending areflexic weakness ± autonomic signs → start IVIg or plasma exchange now. 1
• If descending cranial neuropathies → give BAT now and monitor closely. 2
• If cord signs/AFM/compression → urgent MRI and appropriate specialty pathway. 1
• Check and immediately correct life-threatening electrolytes/toxins. 1, 3